The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting
Julie Vassart a), Alfonso Tafur b) c), Marisa Durante b), Anne-Yseult Boucher a), Laure Morimont a) d), Jeanine M. Walenga e), Job Harenberg f) g), Jonathan Douxfils a) d) h)
a) Clinical Pharmacology and Toxicology Research Unit, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium
b) Vascular Medicine, Department of Medicine. NorthShore University HealthSystem, Evanston, IL, USA
c) University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
d) QUALIblood s.a., QUALIresearch, Namur, Belgium
e) Cardiovascular Research Institute, Stritch School of Medicine, Health Sciences Division, Loyola University Chicago, Maywood, IL, USA
f) Heidelberg University, Heidelberg, Germany
g) DOASENSE, GmbH, Heidelberg, Germany
h) Department of Biological Hematology, CHU Clermont-Ferrand, Hôpital Estaing, France
Highlights
• Preoperative point-of-care test to determine DOAC levels in plasma
• Comparison of the performance of a point-of-care test, UHPLC-MS/MS and a chromogenic assay
• A negative DOAC Dipstick excludes residual levels of FXa inhibitors in plasma.
• Reference standard test significantly impacts the performance of the index test.
• Chromogenic anti-FXa assays should be validated against UHPLC-MS/MS.